LiverAce^™: Detect Liver Injury Earlier and with Greater Confidence

Go beyond the limitations of ALT/AST. Our LiverAce™ Research-Use-Only kits provide highly specific, mechanistically informative data for drug-induced liver injury (DILI) assessment, empowering researchers in pharma, biotech, and CROs to make better decisions, faster.

Request a Quote

A Solution for Every Research Need

Whether you need rapid, specific screening or a deep, mechanistic profile, the LiverAce™ family has you covered.

LiverAce™ COMBO Kit

For comprehensive mechanistic insight, simultaneously measuring miR-122 and Keratin 18.

LiverAce™ SinglePlex Kit

For highly specific and rapid screening, focused on the gold-standard miR-122 biomarker.

Early Detection

Identify hepatocellular injury hours before traditional ALT tests show a signal.

Superior Specificity

Liver-specific miR-122 eliminates false positives from muscle or other tissue damage.

Mechanistic Insight

Differentiate between apoptosis and necrosis via Keratin 18.

Immunoassay-like Protocol

Go from sample to result in under 5 hours with a PCR-free protocol.

Data-Driven Insights

Visually understand the superior performance and biological rationale behind our LiverAce™ biomarkers.

Biomarker Rise After Insult

Adapted from: Chowdhary V et al.. Am J Pathol. 2017 Dec;187(12):2758-2774.

The Destina Advantage: Our Technology

Our proprietary Dynamic Chemical Labelling (DCL) technology enables direct, quantitative, and PCR-free detection.

Direct Detection. No Amplification. No Contamination.

DCL chemistry bypasses enzymatic reactions, reverse transcription, and amplification, eliminating bias and reducing time.

✓
PCR-Free: Avoids amplification errors.
✓
Rapid Turnaround: Results in < 5 hours.
✓
Multiplex Capable: Detect RNA (miR-122) and protein (K18) together.

Simple, Streamlined, Superior

Add Sample

Hybridize

Label

Read

Resources & Publications

User Guides (Protocols)

Request the complete, detailed protocols for the LiverAce™ kits.

Key Publications (Biomarkers)

Clinical evidence supporting miR-122 and Keratin-18 as superior biomarkers.

Key Publications (LiverAce™ on Luminex)

Foundational papers on the Dynamic Chemical Labelling (DCL) technology.

Ready to Transform Your Liver Safety Assessment?

Contact our specialists to discuss your research needs.

LiverAce™: Detect Liver Injury Earlier and with Greater Confidence